BioSpace News Archive

Opdivo plus low-dose Yervoy is the first and only FDA-approved Immuno-Oncology combination therapy for this patient population.

OncoQuest Inc. announced the publication of an abstract, titled “A Phase II Study of Neoadjuvant Chemoimmunotherapy Followed by Stereotactic Radiotherapy/Nelfinavir in Patients with Locally Advanced CA125 Expressing Pancreatic Adenocarcinoma” in the Journal of Clinical Oncology 36, 2018.

CEO Heather Bresch will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Wednesday, June 13, 2018, at 1:20 p.m. PT / 4:20 p.m. ET.

Blue Ridge Orthodontics (BRO) is happy to announce that they will be donating 100% of the profits from their in-house spa services to Mission Children’s Hospital.

Menarini Ricerche (Menarini Group) will present at ASCO Annual Meeting 2018 the study design of CD205-Shuttle.

Company makes effort to connect with patients and caregivers as it progress its potential treatment for an Autistic Spectrum Nonverbal Developmental Disorder

Diagnoses of skin cancers are higher in Massachusetts than the national average and are even higher on Cape Cod, which has the third highest rate of diagnosis in the nation.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in June 2018.

Integral Molecular celebrates a milestone of mapping 1,000 epitopes for customers, collaborators, and the NIH.

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT® (baricitinib), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA).